

Vivek Mittal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4676615/publications.pdf>

Version: 2024-02-01

58
papers

8,640
citations

87888

38
h-index

161849

54
g-index

60
all docs

60
docs citations

60
times ranked

13149
citing authors

#	ARTICLE	IF	CITATIONS
1	Connecting copper and cancer: from transition metal signalling to metalloplasia. <i>Nature Reviews Cancer</i> , 2022, 22, 102-113.	28.4	519
2	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. <i>Science Translational Medicine</i> , 2022, 14, eabe8195.	12.4	16
3	Neutrophil phenotypes and functions in cancer: A consensus statement. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	119
4	52350 PKM2 mediates anti-tumor immunity and T cell dysfunction. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 89-89.	0.6	0
5	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	16.8	93
6	Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 108.	5.2	30
7	Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. <i>Nature Cancer</i> , 2021, 2, 919-931.	13.2	26
8	The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases. <i>Science Advances</i> , 2021, 7, eabg1964.	10.3	18
9	Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. <i>Nature Communications</i> , 2021, 12, 7311.	12.8	101
10	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2020, 30, 755-770.e6.	6.4	65
11	Thrombospondin in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1272, 133-147.	1.6	13
12	Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. <i>ELife</i> , 2020, 9, .	6.0	7
13	Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 579-591.	4.1	56
14	The lung microenvironment: an important regulator of tumour growth and metastasis. <i>Nature Reviews Cancer</i> , 2019, 19, 9-31.	28.4	692
15	Epithelial Mesenchymal Transition in Tumor Metastasis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 395-412.	22.4	896
16	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. <i>JCI Insight</i> , 2018, 3, .	5.0	49
17	Metastatic tumor cells have distinct genotypes and phenotypes. <i>Frontiers in Biology</i> , 2018, 13, 277-286.	0.7	10
18	Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor. <i>Neoplasia</i> , 2017, 19, 55-64.	5.3	45

#	ARTICLE	IF	CITATIONS
19	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. Journal of Cell Biology, 2017, 216, 641-656.	5.2	35
20	Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis. Science Translational Medicine, 2017, 9, .	12.4	91
21	Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments. , 2017, , 303-328.		0
22	Fischer et al. reply. Nature, 2017, 547, E5-E6.	27.8	21
23	Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. Clinical Cancer Research, 2017, 23, 666-676.	7.0	140
24	A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results.. Journal of Clinical Oncology, 2017, 35, 2557-2557.	1.6	7
25	Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. Oncotarget, 2016, 7, 85437-85449.	1.8	26
26	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science Translational Medicine, 2016, 8, 329ra34.	12.4	54
27	<i>In Vivo</i> Visualization and Characterization of Epithelialâ€Mesenchymal Transition in Breast Tumors. Cancer Research, 2016, 76, 2094-2104.	0.9	64
28	The Microenvironment of Lung Cancer and Therapeutic Implications. Advances in Experimental Medicine and Biology, 2016, 890, 75-110.	1.6	96
29	Epithelial Mesenchymal Transition in Aggressive Lung Cancers. Advances in Experimental Medicine and Biology, 2016, 890, 37-56.	1.6	66
30	Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget, 2016, 7, 39957-39969.	1.8	49
31	Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS ONE, 2015, 10, e0129123.	2.5	17
32	Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 16000-16005.	7.1	168
33	Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer Model. Cell Reports, 2015, 10, 1187-1201.	6.4	137
34	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 2015, 527, 472-476.	27.8	1,498
35	Altering the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence.. Journal of Clinical Oncology, 2015, 33, 11008-11008.	1.6	3
36	Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8838-8843.	7.1	99

#	ARTICLE	IF	CITATIONS
37	ID Proteins Regulate Diverse Aspects of Cancer Progression and Provide Novel Therapeutic Opportunities. <i>Molecular Therapy</i> , 2014, 22, 1407-1415.	8.2	46
38	Suppression of miRNA-708 by Polycomb Group Promotes Metastases by Calcium-Induced Cell Migration. <i>Cancer Cell</i> , 2013, 23, 63-76.	16.8	135
39	Bone Marrow-Derived Gr1+ Cells Can Generate a Metastasis-Resistant Microenvironment Via Induced Secretion of Thrombospondin-1. <i>Cancer Discovery</i> , 2013, 3, 578-589.	9.4	113
40	Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. <i>Breast Cancer Research</i> , 2012, 14, 202.	5.0	204
41	Tumor microenvironment regulates epithelial-mesenchymal transitions in metastasis. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 857-859.	2.4	14
42	Microenvironmental Regulation of Epithelial-Mesenchymal Transitions in Cancer. <i>Cancer Research</i> , 2012, 72, 4883-4889.	0.9	265
43	Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. <i>Cancer Research</i> , 2012, 72, 1384-1394.	0.9	261
44	Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 235-242.	2.5	31
45	Discovery of Novel Human Breast Cancer MicroRNAs from Deep Sequencing Data by Analysis of Pri-MicroRNA Secondary Structures. <i>PLoS ONE</i> , 2011, 6, e16403.	2.5	29
46	Using the Transcription Factor Inhibitor of DNA Binding 1 to Selectively Target Endothelial Progenitor Cells Offers Novel Strategies to Inhibit Tumor Angiogenesis and Growth. <i>Cancer Research</i> , 2010, 70, 7273-7282.	0.9	63
47	TGF- β 2 IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15535-15540.	7.1	356
48	Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 33-40.	7.4	99
49	The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. <i>Trends in Molecular Medicine</i> , 2009, 15, 333-343.	6.7	91
50	Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis. <i>Science</i> , 2008, 319, 195-198.	12.6	609
51	Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, E54; author reply E55.	7.1	51
52	Depletion of Vascular Endothelial Progenitor Cells Inhibits Inflammation. <i>Blood</i> , 2008, 112, 694-694.	1.4	0
53	ID genes mediate tumor reinitiation during breast cancer lung metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19506-19511.	7.1	238
54	Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. <i>Genes and Development</i> , 2007, 21, 1546-1558.	5.9	360

#	ARTICLE	IF	CITATIONS
55	Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization. PLoS ONE, 2007, 2, e267.	2.5	45
56	Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation. PLoS ONE, 2007, 2, e1338.	2.5	66
57	Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell, 2003, 4, 277-289.	16.8	238
58	Signal transduction in tumor angiogenesis. , 0, , 861-871.		0